Modified nucleoside triphosphates
A proven solution for mRNA therapeutic development
The use of modified nucleoside triphosphates (NTPs) has been instrumental in advancing mRNA therapeutic innovation, and TriLink® has been partnering with mRNA pioneers since day one. Our modified NTPs are used in vaccine and therapeutic programs worldwide and continue to fuel the development of novel therapeutics. From research use to the first-ever GMP-grade offering, TriLink provides a comprehensive portfolio of off-the-shelf, scalable, chemically synthesized NTP to help accelerate your mRNA therapeutic or vaccine development.
Promote robust expression and minimize immunogenicity
Incorporating modified uridines into mRNA products help reduce immunogenicity, enhance mRNA stability, and increase translational capacity for more successful therapeutic action. To help you optimize mRNA performance, TriLink offers >150 modified NTPs in catalog and customizable formats—from RUO to GMP-grade—for your diverse applications.
Widely used modified NTPs in mRNA therapeutic development
N1-Methyl-Pseudouridine-5'-Triphosphate
5-Methoxyuridine-5'-Triphosphate
Pseudouridine-5'-Triphosphate
5-Methylcytidine-5'-Triphosphate
Related videos
Related products and services
Contact us for a quote or more information about nucleotides.
Complete the form below and our team will contact you shortly.
